Gene therapy of viral hepatitis and hepatocellular carcinoma

Journal of Viral Hepatitis

Volumn 6, Issue 1, 1999, Pages 17-34

  Ruiz, J ^a   Qian, C ^a   Drozdzik, M ^a   Prieto, J ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Cancer; Gene therapy; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

COMPLEMENTARY DNA; COMPLEMENTARY RNA; CYTOKINE; FLUCYTOSINE; FLUOROURACIL; INTERLEUKIN 2; RIBOZYME; VIRUS ANTIGEN; VIRUS VECTOR;

GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNIZATION; INFECTION RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUICIDE GENE; VIRUS HEPATITIS;

CARCINOMA, HEPATOCELLULAR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS;

EID: 0033024418     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.6120136.x     Document Type: Review

References (204)

1. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460.
2. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
3. Ledley FD. Hepatic gene therapy: present and future. Hepatology 1993; 18: 1263-1273.
4. Chang AGY, Wu GY. Gene therapy. Applications to the treatment of gastrointestinal and liver diseases. Gastroenterology 1994; 106: 1076-1084.
5. Crooke ST. Basic principles of antisense therapeutics. In: Crooke ST, ed. Antisense Research and Application. Handbook of Experimental Pharmacology. Vol. 131. Berlin: Springer, 1998: 1-50.
6. Eguchi Y. Antisense RNA. Annu Rev Biochem 1991; 60: 631-652.
7. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988; 334: 585-591.
8. Symons RH. Ribozymes. Curr Opin Struct Biol 1994; 4: 322-330.
9. Sullenger BA, Gallardo FH, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 1991; 65: 6811-6816.
10. Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987; 329: 219-222.
11. Chen SY, Bagley J, Marasco WA. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Human Gene Ther 1994; 5: 595-601.
12. Gordon EM, Anderson WF. Gene therapy using retroviral vectors. Curr Opin Biotechnol 1995; 6: 611-616.
13. Boris-Lawrie K, Temin HM. The retroviral vector. Replication cycle and safety considerations for retrovirus-mediated gene therapy. Ann NY Acad Sci 1994; 716: 50-70.
14. Kitten O, Cosset FL, Ferry N. Highly efficient retrovirusmediated gene transfer into rat hepatocytes in vivo. Human Gene Ther 1997; 8: 1491-1494.
15. Friedman T, Yee JK. Pseudotyped retroviral vectors for studies of human gene therapy. Nature Med 1995; 1: 275-277.
16. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentivirus vector. Science 1996; 272: 2683-2687.
17. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genet 1997; 17: 314-317.
18. Kovesdi I, Borugh DE, Bruder JT, Wickham TJ. Adenoviral vectors for gene transfer. Curr Opin Biotechnol 1997; 8: 583-589.
19. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
20. Yang Y, Hildegund CJE, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
21. Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 1997; 11: 615-623.
22. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 1997; 4: 1069-1076.
23. Bartlett JS, Quattrocchi KB, Samulski RJ. The development of adeno-associated virus as a vector for cancer gene therapy. In: Sobol RE, Scanlon KJ, eds. The Internet Book of Gene Therapy, Stamford: Appleton & Lange, 1995: 27-39.
24. Ponnazhagan S, Mukherjee P, Yoder MC et al. Adeno-associated virus 2-mediated gene transfer in vivo: organtropism and expression of transduced sequences in mice. Gene 1997; 190: 203-210.
25. Snyder RO, Miao CH, Patijn GA et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genet 1997; 16: 270-276.
26. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA 1995; 92: 5719-5723.
27. Alexander IE, Russell DW, Spence AM, Miller AD. Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Human Gene Ther 1996; 7: 841-850.
28. Koeberl DD, Alexander IE, Halbert CL, Russell DW. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 1997; 94: 1426-1431.
29. Ledley F. Non viral gene therapy: the promise of genes as pharmaceutical products. Human Gene Ther 1995; 6: 1129-1144.
30. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
31. Hickman MA, Malone RW, Lehmann-Bruinsma K et al. Gene expression following direct injection of DNA into liver. Human Gene Ther 1994; 4: 1477-1483.
32. Zhang G, Vargo D, Budker V, Armstrong N, Knechtle S, Wolff JA. Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Human Gene Ther 1997; 8: 1763-1772.
33. Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 1989; 337: 387-388.
34. Crespo J, Blaya C, Crespo A, Aliño SF. Long-term expression of the al-antitrypsin gene in mice employing anionic and cationic liposome vectors. Biochem Pharmacol 1996; 51: 1309-1314.
35. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Human Gene Ther 1997; 8: 2133-2141.
36. Holmberg EG, Reuer QR, Geisert EE, Owens JL. Delivery of plasmid DNA to glial cells using pH-sensitive immunoliposomes. Biochem Biophys Res Commun 1994; 201: 888-893.
37. Wu GY, Wu CH. Receptor mediated gene delivery and expression in vivo. J Biol Chem 1988; 263: 14621-14624.
38. Wu CH, Wilson JM, Wu GY. Trageting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J Biol Chem 1989; 264: 16985-16987.
39. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW. Gene transfer in vivo: sustained expression and regulation of genes introduced into liver by the receptor-targeted uptake. Proc Natl Acad Sci USA 1994; 91: 4086-4090.
40. Perales JC, Grossman GA, Molas M et al. Biochemical and functional characterization of DNA complexes capable of targeting genes to hepatocytes via the asyaloglycoprotein receptor. J Biol Chem 1997; 272: 7398-7407.
41. Tang DC, Devit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-154.
42. 2+ flux. Biochem Biophys Res Commun 1997; 234: 695-700.
43. Chattergoon M, Boyer J, Weiner DB. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J 1997; 11: 753-763.
44. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997; 100: 519-524.
45. Ulmer JB, Donnelly J, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
46. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617-648.
47. Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997; 186: 1481-1486.
48. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998; 19: 89-97.
49. Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as Th1 promoting adjuvants. Nature Med 1997; 3: 849-854.
50. Sparwasser T, Koch ES, Vabulas RM et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28: 2045-2054.
51. Kim JJ, Ayyavoo V, Bagarazzi ML et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158: 816-826.
52. Tsuji T, Hamjima K, Fukushima J et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997; 158: 4008-4013.
53. Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997; 158: 4591-4601.
54. Kim JJ, Bagarazzi ML, Trivedi N et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nature Biotech 1997; 15: 641-646.
55. Pertmer TM, Eismbraun MD, McCabe D, Prayaga SK, Fuller DH, Haynes JR. Gene-gun based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 1995; 13: 1427-1430.
56. Gregoriadis G, Sakkie R, Brian de Souza J. Liposomemediated DNA vaccination. FEBS Lett 1997; 402: 107-110.
57. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nature Med 1998; 4: 365-368.
58. Bruña-Romero O, Lasarte JJ, Wilkinson G et al. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 1997; 25: 470-477.
59. Townsend K, Sallberg M, OíDea J et al. Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens. J Virol 1997; 71: 3365-3374.
60. He XS, Rivkina M, Robinson WS. Construction of adenoviral and retroviral vectors coexpressing the genes encoding the hepatitis B surface antigen and B7-1 protein. Gene 1996; 175: 121-125.
61. Weizsacker FV, Wieland S, Lock J et al. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 1997; 26: 251-255.
62. Davis HL, Michel ML, Mancini M, Schleef M, Whalen RG. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine 1994; 12: 1503-1509.
63. Davis HL, Schirmbeck R, Reimann J, Whalen RG. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to hepatitis B surface antigen. Human Gene Ther 1995; 6: 1447-1456.
64. Schirmbeck R, Bohm W, Ando K, Chisari FV, Reimann J. Nucleic acid vaccination primes hepatitis B surface antigen-specific cytotoxic T lymphocytes in non-respondermice. J Virol 1995; 69: 5929-5934.
65. He WS, Chen HS, Chu K, Rivkina M, Robinson WS. Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen. Proc Natl Acad Sci USA 1996; 93: 7274-7278.
66. Kuhober A, Pudoller HP, Reifenberg K et al. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J Immunol 1996; 156: 3687-3695.
67. Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human Mol Genet 1993; 2: 1847-1851.
68. Michel ML, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 1995; 92: 5307-5311.
69. Davis HL, Mancini M, Michel ML, Whalen RG. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine 1996; 14: 910-915.
70. Geissler M, Tokushige K, Chante CC, Zurawski VR, Wands JR. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization. Gastroenterology 1997; 112: 1307-1320.
71. Chow YH, Huang WL, Chi WK, Chu YD, Tao MH. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997; 71: 169-178.
72. Geissler M, Schirmbeck R, Reinmann J, Blum HE, Wands JR. Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not the large hepatitis B virus surface antigen in mice. Hepatology 1998; 28: 202-210.
73. Chow YH, Chiang BL, Lee YL et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokinc genes. J Immunol 1998; 160: 1320-1329.
74. Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence for immunogencity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 1996; 93: 7213-7218.
75. Gramzinski RA, Brazolot CL, Obaldia N, Hoffman SL, Davis HL. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med 1998; 4: 109-118.
76. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 1996; 93: 12946-12501.
77. Guidotti LG, Ando K, Hobbs MV et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 3764-3768.
78. Tsui LV, Guidotti LG, Ishikawa T, Chisari FV. Post-transcriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci USA 1995; 92: 12398-12402.
79. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
80. Goodarzi G, Gross SC, Tewari A, Watabe K. Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. J Gen Virol 1990; 71: 3021-3025.
81. Blum HE, Galun E, Weizsacker FV, Wands JR. Inhibition of hepatitis B virus by antisense oligodeoxynucleotides. Lancet 1991; 337: 1230.
82. Wu GY, Wu CH. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 1992; 267: 12436-12439.
83. Nakazono K, Ito Y, Wu CH, Wu GY. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 1996; 23: 1297-1303.
84. Yao ZQ, Zhou YX, Feng XM, Chen ZX. Specific inhibition of hepatitis B virus gene expression by an antisense oligonucleotide in vitro. Acta Virol 1995; 39: 227-230.
85. Madon J, Blum HE. Receptor-mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian cells. Hepatology 1996; 24: 474-481.
86. Yao ZQ, Zhou YX, Guo J et al. Inhibition of hepatitis B virus in vitro antisense oligonucleotides. Acta Virol 1996; 40: 35-39.
87. Ji W, St CW. Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA. J Viral Hep 1997; 4: 167-173.
88. Wu J, Gerber MA. The inhibitory effect of antisense RNA on hepatitis virus surface antigen synthesis. J Gen Virol 1997; 78: 641-647.
89. Weiszacker FV, Blum HE, Wands JR. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochem Biophys Res Commun 1992; 189: 743-748.
90. Beck J, Nassal M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucl Acids Res 1995; 23: 4954-4962.
91. Ruiz J, Ito Y, Wu CH, Wu GY. Design and preparation of a multimeric self-cleaving hammerhead ribozyme. Biotechniques 1997; 22: 338-345.
92. Welch PJ, Tritz R, Yei S, Barber J, Yu M. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 1997; 4: 736-743.
93. Weiszacker FV, Wieland S, Blum HE. Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein. Hepatology 1996; 24: 294-299.
94. Scaglioni PP, Melegari M, Takahashi M, Chowdhury JR, Wands JR. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996; 24: 1010-1017.
95. Sells MA, Zelent AZ, Shvartsman M, Acs G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol 1988; 62: 2836-2844.
96. Offensperger WB, Offensperger S, Walter E et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorotioate modified antisense oligodeoxynucleotides. EMBO J 1993; 12: 1257-1262.
97. Yao Z, Chou Y, Feng X, Chen C, Guo J. In vivo inhibition of hepatitis B viral gene expression by antisense phosphorotioate oligodeoxynucleotides in athymic nude mice. J Viral Hep 1996; 3: 19-22.
98. Moriya K, Matsukura M, Kurokawa K, Koike K. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Biochem Biophys Res Commun 1996; 218: 217-223.
99. Bartholomew RM, Carmichael EP, Findeis MA, Wu CH, Wu GY. Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks. J Viral Hep 1995; 2: 273-278.
100. Lagging LM, Meyer K, Hoft D, Houghton M, Belshe RB, Ray R. Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 1995; 69: 5859-5863.
101. Major ME, Vitvitski L, Mink MA et al. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol 1995; 69: 5798-5805.
102. Tokushige K, Wakita T, Pachuk C et al. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 1996; 24: 14-20.
103. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997; 158: 1231-1237.
104. Inchauspe G, Vitvitski L, Major ME et al. Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997; 16: 185-195.
105. Inchauspe G, Major ME, Nakano I, Vitvitski L, Trepo C. DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 1997; 15: 853-856.
106. Saito T, Sherman GJ, Kurokohchi K et al. Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice. Gastroenterology 1997; 112: 1321-1330.
107. Nakano I, Maertens G, Major ME et al. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 1997; 71: 7101-7109.
108. Fournillier A, Nakano I, Vitvitski L et al. Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes. Hepatology 1998; 28: 237-244.
109. Makimura M, Miyake S, Takamori AN et al. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 1996; 14: 28-36.
110. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706-714.
111. Wakita T, Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J Biol Chem 1994; 269: 14205-14210.
112. Mizutani T, Kato N, Hirota M, Sugiyama K, Murakami A, Shimotohno K. Inhibition of hepatitis C virus replication by antisense oligonucleotide in cultured cells. Biochem Biophys Res Commun 1995; 212: 906-911.
113. Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WH. Specific inhibition of hepatitis C viral gene expression by antisense phosphorotioate oligodeoxynucleotides. Hepatology 1995; 22: 707-717.
114. Hanecak R, Brown-Driver V, Fox MC et al. Antisense oligonucleotide inhibition of hepatitis C gene expression in transformed hepatocytes. J Virol 1996; 70: 5203-5212.
115. Lima WF, Brown-Driver V, Fox M, Hanecak R, Bruice TW. Combinatorial screening and a rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J Biol Chem 1997; 272: 626-638.
116. Alt M, Renz R, Hofschneider PH, Caselmann WH. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation. Arch Virol 1997; 142: 589-599.
117. Wu CH, Wu Gy. Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines. Gastroenterology 1998; 114: 1304-1312.
118. Lieber A, He CY, Polyak SJ, Gretch DR, Barr D, Kay MA. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996; 70: 8782-8791.
119. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996; 98: 2720-2728.
120. Gore ME, Collins MK. Gene therapy for cancer. Eur J Cancer 1994: 30A: 1047-1049.
121. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 1992; 339: 715-721.
122. Culver KW, Blaese RM. Gene therapy for cancer. Trends Genet 1994; 10: 174-178.
123. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
124. Kimura O, Yamaguchi Y, Gunning KB, Teeter LD, Husain F, Kuo MT. Retroviral delivery of DNA into the livers of transgenic mice bearing premalignant and malignant hepatocellular carcinomas. Human Gene Ther 1994; 5: 845-852.
125. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15: 225-236.
126. Sato Y, Nakata K, Kato Y et al. Early recognition of hepatocellular carcinoma based on altered profiles of alphafetoprotein. N Engl J Med 1993; 328: 1802-1806.
127. Watanabe K, Saito A, Tamacki T et al. Cell-specific enhancer activity in a far upstream region of the human α-fetoprotein gene. J Biol Chem 1987; 262: 4812-4818.
128. Nakabayashi H, Hashimoto T, Miyao Y, Tjong KK, Chan J, Tamaoki T. A position-dependent silencer plays a major role in repressing α-fetoprotein expression in human hepatoma. Mol Cell Biol 1991; 11: 5885-5893.
129. Poliard A, Bakkali L, Poiret M, Foiret D, Danan JL. Regulation of the rat α-fetoprotein gene expression in liver. J Biol Chem 1990; 265: 22137-22141.
130. Widen SG, Papaconstantinou J. Liver-specific expression of the mouse α-fetoprotein gene is mediated by cis-acting DNA elements. Proc Natl Acad Sci USA 1986; 83: 8196-8200.
131. Arbuthnot P, Bralet M-P, Thomassin H, Danan J-L, Brechet C, Ferry N. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by α-feto-protein but not insulin-like growth factor II regulatory sequences. Hepatology 1995; 22: 1788-1796.
132. Arbuthnot P, Bralet MP, Le Jossic C et al. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Human Gene Ther 1996; 7: 1503-1514.
133. Kanai F, Shiratori Y, Yoshida T et al. Gene therapy for α-fetoprotein-producing human hepatoma cell lines by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 1996; 23: 1359-1367.
134. Su H, Chang JC, Xu SM, Kan YW. Selective killing of AFP-positive hepatocellular carcinoma cells by adenoassociated virus transfer of the herpes simplex virus thymidine kinase. Human Gene Ther 1996; 7: 463-470.
135. Nakabayashi H, Watanabe K, Saito A, Otsuru A, Sawadaishi K, Tamaoki T. Transcriptional regulation of α-fetoprotein expression by dexamethasone in human hepatoma cells. J Biol Chem 1989; 264: 266-271.
136. Ido A, Nakata K, Kato Y et al. Gene therapy for hepatoma cells using a retroviral vector carrying herpes simplex virus thymidine kinase gene under control of human alpha-fetoprotein gene promoter. Cancer Res 1995; 55: 3105-3109.
137. Bui LA, Butterfield LH, Kim JY et al. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin 2. Human Gene Ther 1997; 8: 2173-2182.
138. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57: 1-9.
139. Huetow KH, Sheffield VC, Zhu M et al. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci USA 1992; 89: 9622-9626.
140. Unsal H, Yakicier C, Marçais C et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 1994; 91: 822-826.
141. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol 1995; 69: 1851-1859.
142. Ueda H, Ullrich SJ, Gangemi JD et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet 1995; 9: 41-47.
143. Lowe SW, Ruley HR, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
144. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal cell growth by wild-type p53. Science 1990; 249: 912-915.
145. Wang NP, To H, Lee W-H, Lee EY-HP. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 1993; 8: 279-288.
146. Liu T, Zhang W, Taylor DL. Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-3667.
147. Glaymann GL, El-Naggar AK, Roth JA et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1-6.
148. Wills KN, Maneval DC, Menzel P et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Human Gene Ther 1994; 5: 1079-1088.
149. Fujiwara T, Cai DW, Georges RN, Mukhopahyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-1462.
150. Qian C, Prieto J. Growth Suppression of Human hepato-cellular carcinoma (HCC) cells by the introduction of wild-type p53 (WT-p53). J Hepatol 1994; 21: S9.
151. Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 1996; 24: 1264-1268.
152. Bookstein R, Demers W, Gregory R, Maneval D, Park J, Willis K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 1996; 23: 66-77.
153. Hu LF, Wang LP, Huang LH, Li XL, Li XE, Gu JE. Expression of N-ras gene in human primary hepatocarcinoma. Sci Sin B 1986; 29: 181-186.
154. Jia L, Wang X, Xu X et al. Construction and packaging of pseudotype retrovirus containing human N-ras cDNA antisense sequence and its biological effects on human hepatoma cells. Cell Res 1990; 2: 132-141.
155. Huang XM, Wei SG, Wang LF. Reversal of malignant phenotype of human hepatoma cells by antisense c-ets-2, c-myc and N-ras. Chung Hua Chung Liu Tsa Chin 1994; 16: 243-246.
156. Maret A, Galy B, Arnaud E, Bayard F, Prats H. Inhibition of fibroblast growth factor 2 expression by antisense RNA induced a loss of the transformed phenotype in a human hepatoma cell line. Cancer Res 1995; 55: 075-5079.
157. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
158. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
159. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
160. Chen S, Shine HD, Goodman JC, Grossman RG, Woo SLC. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
161. Hwang HC, Smythe WR, Elshami AA et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models for human malignant mesothelioma and lung cancer. Am J Respir Cell Biol 1995; 13: 7-16.
162. Qian C, Bilbao R, Bruña O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 1995; 22: 118-123.
163. Freeman SM, Abboud CN, Whartenby KA et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
164. Chen CY, Chang YN, Ryan P, Linscott M, McGarrity G, Chiang YL. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the 'bystander effect'. Human Gene Ther 1995; 6: 1467-1476.
165. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vivo evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Human Gene Ther 1993; 4: 725-731.
166. Fick J, Barker II FG, Dazin P, Westphale EM, Beyer EC, Israel MA. The extent of heterocellular communication mediated by gap junctions is preditive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995; 92: 11071-11075.
167. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
168. Kianmanesh AR, Perrin H, Panis Y et al. A 'distant' bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distanr transduced tumor. Human Gene Ther 1997; 8: 1807-1814.
169. Will KN, Huang WM, Harris MP, Machemer T, Maneval DC, Gregory RJ. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther 1995; 2: 191-197.
170. Kuriyama S, Nakatani T, Masui K et al. Evaluation of prodrugs' ability to induce effective ablation of cells transduced with viral thymidine kinase gene. Anticancer Res 1996; 16: 2623-2628.
171. Qian C, Iodate M, Bilbao R et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Human Gene Ther 1997; 8: 349-358.
172. van der Eb MM, Cramer SJ, Vergouwe Y et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther 1998; 5: 451-458.
173. Brand K, Arnold W, Bartels T et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther 1997; 4: 9-16.
174. Kaneko S, Hallenbeck P, Kotani T et al. Adenovirusmediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995; 55: 5283-5287.
175. Topf N, Worgall S, Hacknett NR, Crystal RG. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther 1998; 5: 507-513.
176. Kanai F, Lan K-H, Shiratori Y et al. In vivo gene therapy for α-fetoprotein-producing hepatocelluar carcinoma by adenovirus-mediated transfer of the cytosine deaminase gene. Cancer Res 1997; 57: 461-465.
177. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88: 8039-8043.
178. Usuda S, Yoshizawa K, Yabu K, Kiyosawa K. Immunological responses against an autologous human hepatocellular carcinoma cell line. J Gastroenterol Hepatol 1993; 8: 517-523.
179. Kawata A, Une Y, Hosokawa M, Uchino J, Kobayashi H. Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol 1992; 22: 256-263.
180. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493-497.
181. Roth C, Rochlitz C, Kourilsky P. Immune response against tumors. Adv Immunol 1994; 57: 281-351.
182. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhbits the functional maturation of dendritic cells. Nature Med 1996; 2: 1096-1103.
183. Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today 1996; 17: 39-45.
184. Musiani P, Modesti A, Giovarella M et al. Cytokine, tumor-cell death and immunogenicity: a question of choice. Immunol Today 1997; 18: 32-36.
185. Schmidt-Wolf G, Schmidt-Wolf GH. Cytokines and gene therapy. Immunol Today 1995; 16: 173-175.
186. Colombo M, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994; 15: 48-51.
187. Cao G, Kuriyama S, Du P et al. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor α gene transfer. Gastroenterology 1997; 112: 501-510.
188. Sun Y, Qian C, Peng D, Prieto J. Immunotherapy of hepatocellular carcinoma (HCC) by engineering tumor cells to express B7-1 and/or IL-12. J Hepatol 1998; 28: S59.
189. Huang H, Chen SH, Kosai K, Finegold MJ, Woo SLC. Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther 1996; 3: 980-987.
190. Schwartz R. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065-1068.
191. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321-331.
192. Chen L, Ashe S, Brady WA et al. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
193. Tatsumi T, Takehara T, Katayama K, Mochizuki K, Yamamoto M, Kanto T. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology 1997; 25: 1108-1114.
194. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
195. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy. Immunol Today 1995; 16: 117-121.
196. Girolomoni G, Ricciardi-Castagnoli P. Dendritic cells hold promise for immunotherapy. Immunol Today 1997; 18: 102-104.
197. Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Human Gene There 1997; 8: 1355-1363.
198. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 52-58.
199. Specht JM, Wang G, Do MT et al. Dendritic cells retrovirally transduced with a model tumor antigen gene are therapeutic effective against established pulmonary metastasis. J Exp Med 1997; 186: 1213-1221.
200. Lai C, Chien R, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
201. Lasarte JJ, Garcia-Granero M, Lopez A et al. Cell immunity to HCV core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998; 28: 815-822.
202. Molema G, de Leij LF, Meijer DK. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharmacol Res 1997; 14: 2-10.
203. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nature Med 1998; 4: 655-657.
204. Bilbao R, Qian C, Drozdzik M, Pajares MJ, Prieto J. Vasoactive compounds increase the efficiency of adenoviral gene transfer to primary liver tumors. J Hepatol 1998; 28: S143.